A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Herrera, Bobby Brooke, Donald J. Hamel, Philip Oshun, Rolake Akinsola, Alani S. Akanmu, Charlotte A. Chang, Philomena Eromon, et al. 2018. "A Modified Anthrax Toxin-Based Enzyme-Linked Immunospot Assay Reveals Robust T Cell Responses in Symptomatic and Asymptomatic Ebola Virus Exposed Individuals.” Edited by Manuel Schibler. PLOS Neglected Tropical Diseases 12 (5) (May 24): e0006530. doi:10.1371/journal.pntd.0006530.

Published Version
10.1371/journal.pntd.0006530

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:37221722

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals

Bobby Brooke Herrera1, Donald J. Hamel1, Philip Oshun2, Rolake Akinsola3, Alani S. Akanmu2, Charlotte A. Chang1, Philomena Eromon4, Onikepe Folarin4,5, Kayode T. Adeyemi5, Christian T. Happi4,5, Yichen Lu6, Folasade Ogunnola2, Phyllis J. Kanki1*

1 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America, 2 College of Medicine, University of Lagos, Akoka, Lagos, Nigeria, 3 Lagos University Teaching Hospital, Idi Oro, Lagos, Nigeria, 4 African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer’s University, Ede, Osun State, Nigeria, 5 Department of Biological Sciences, College of Natural Sciences, Redeemer’s University, Ede, Osun State, Nigeria, 6 Haikou VTI Biological Institute, Haikou, Hainan, China

* pkanki@hsph.harvard.edu

Abstract

Background

Ebola virus (EBOV) caused more than 11,000 deaths during the 2013–2016 epidemic in West Africa without approved vaccines or immunotherapeutics. Despite its high lethality in some individuals, EBOV infection can produce little to no symptoms in others. A better understanding of the immune responses in individuals who experienced minimally symptomatic and asymptomatic infection could aid the development of more effective vaccines and antivirals against EBOV and related filoviruses.

Methodology/Principle findings

Between August and November 2017, blood samples were collected from 19 study participants in Lagos, Nigeria, including 3 Ebola virus disease (EVD) survivors, 10 individuals with documented close contact with symptomatic EVD patients, and 6 control healthcare workers for a cross-sectional serosurvey and T cell analysis. The Lagos samples, as well as archived serum collected from healthy individuals living in surrounding areas of the 1976 Democratic Republic of Congo (DRC) epidemic, were tested for EBOV IgG using commercial enzyme-linked immunosorbent assays (ELISAs) and Western blots. We detected antibodies in 3 out of 3 Lagos survivors and identified 2 seropositive individuals not known to have ever been infected. Of the DRC samples tested, we detected antibodies in 9 out of 71 (12.7%). To characterize the T cell responses in the Lagos samples, we developed an anthrax toxin-based enzyme-linked immunospot (ELISPOT) assay. The seropositive asymptomatic individuals had T cell responses against EBOV nucleoprotein, matrix protein, and glycoprotein 1 that were stronger in magnitude compared to the survivors.
Conclusion/Significance

Our data provide further evidence of EBOV exposure in individuals without EVD-like illness and, for the first time, demonstrate that these individuals have T cell responses that are stronger in magnitude compared to severe cases. These findings suggest that T cell immunity may protect against severe EVD, which has important implications for vaccine development.

Author summary

The 2013–2016 West African Ebola virus (EBOV) outbreak is the largest on record with over 28,000 reported symptomatic cases and more than 11,000 deaths. We developed a simple and inexpensive modified anthrax toxin-based ELISPOT assay to detect and characterize the T cell responses elicited by prior exposure to EBOV. Our data show robust T cell responses to several EBOV proteins in individuals who experienced both severe and asymptomatic EBOV infections. These results provide further evidence that EBOV transmission events can go undetected. We also show that the seropositive asymptomatic individuals have stronger T cell responses compared to survivors, which has important implications for vaccine development.

Introduction

Ebola viruses including the five antigenically distinct species, Bundibugyo ebolavirus (BDBV), Reston ebolavirus (RESTV), Tai Forest ebolavirus (TAFV), Sudan ebolavirus (SUDV), and Zaire ebolavirus (EBOV), are enveloped filamentous viruses belonging to the family Filoviridae [1–3]. These viruses carry negative strand RNA genomes approximately 19 kb in length that code for 7 structural proteins: the nucleoprotein (NP), VP35, the matrix protein (VP40), the glycoprotein (GP), VP30, VP24, and the RNA-dependent RNA polymerase [1].

Since the discovery of EBOV in 1976 in the Democratic Republic of Congo (DRC), BDBV, SUDV, and EBOV have caused sporadic epidemics of lethal hemorrhagic fever or Ebola virus disease (EVD), largely in Central Africa, with case fatality rates of 23–90% [4–7]. In December 2013, an outbreak of EBOV was detected in Guinea, which led to the largest ever recorded epidemic spanning seven West African countries. By 2016, more than 28,000 symptomatic cases of EVD were reported with a case fatality rate of 40% [8]. Although there are several in the pipeline, there are currently no licensed vaccines against EBOV and treatment remains largely supportive.

Richardson et al. recently conducted a survey of close household contacts of individuals who had severe EVD and showed that a significant portion of EBOV transmission events went undetected during the West African outbreak because some individuals contracted infection but had mild illness or were asymptomatic [9]. This work adds to a growing body of evidence suggesting that despite its high lethality in some individuals, EBOV infection can produce little to no symptoms in others [10]. Seroprevalence surveys conducted in Africa have historically described asymptomatic EBOV infection, however, due to uncertainty in serologic assays, consensus on the significance of these findings has not been reached. Nonetheless, while several hypotheses might explain minimally symptomatic and asymptomatic EBOV infection, including properties of the infecting virus (e.g. less virulent isolate), low inoculum, route of
transmission, host factors (e.g. resistance through viral cell receptor polymorphism), or a robust innate and/or adaptive immune response are potential explanations.

Antibody therapy is considered an effective and powerful treatment strategy against many infectious pathogens. While studies of whole-blood transfusion or serum as passive immunity for EBOV treatment have demonstrated limited efficacy, monoclonal antibodies have shown promise in animal models and have been tested in human clinical trials [11–15]. The most successful of these is the antibody cocktail ZMapp, which comprises three humanized murine monoclonal antibodies that target the EBOV GP. ZMapp reversed advanced disease and rescued 100% of rhesus macaques up to 5 days post-viral challenge; however, it did not meet a pre-specified threshold for efficacy in humans when tested during the 2013–2016 outbreak [13, 16].

Immune depletion studies in the macaque EBOV model demonstrated that humoral responses were beneficial in containing virus, but CD8+ T cells were essential for vaccine-induced protection. These findings suggest that humoral immunity alone may not account for full recovery or secondary protection. T cell responses of appropriate quality and magnitude were shown to be important for human protection against EBOV [17–19]. During the West African outbreak, Ruibal et al. demonstrated unique mechanisms that regulate T cell homeostasis in fatal and non-fatal EVD cases, suggesting that EBOV infections can trigger T cell responses that may be more effective in some individuals than others [20]. More studies are needed to better understand the immunopathogenesis of EVD, especially in mildly symptomatic or asymptomatic cases.

In this study, we adapted the modified anthrax lethal factor (LFn) delivery system to enable the detection and characterization of T cell responses in previously EBOV exposed individuals from Lagos, Nigeria, three years after the outbreak. We fused the EBOV (Makona variant) NP, VP40, and the receptor binding subunit of GP, known as GP1, to LFn. The LFn-EBOV recombinant proteins were expressed and used as antigens to stimulate peripheral blood mononuclear cells (PBMCs) in an ELISPOT assay. We report robust T cell responses in EVD survivors and in EBOV seropositive asymptomatic individuals.

Methods

Ethics statement

The protocols used in this study were approved by the Health Research Ethics Committee at the College of Medicine, University of Lagos, Nigeria (CM/HREC/09/16/055) and by the Internal Review Board (IRB) at the Harvard T.H. Chan School of Public Health (Harvard Chan), Boston, USA (Protocol number IRB16-1321). All study participants included in the study were adults. The participants from Lagos provided written informed consent for the collection of samples and corresponding data were banked and de-identified prior to analyses. The DRC samples were collected under surveillance in 1976. The samples were anonymized by the US CDC prior to shipment to Harvard Chan in 1985.

Study populations

On 20 July 2014 an individual who travelled from Liberia presenting with fever was transported to a private hospital in Lagos; he denied contact with known EVD cases and was treated with antimalarial drugs [21]. The individual’s condition worsened over the next three days, at which point EVD was suspected. Filovirus and EBOV-specific PCR testing was performed by Lagos University Teaching Hospital (LUTH) and Redeemer’s University (RUN) African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), respectively, and the patient was confirmed EVD positive on 25 July 2014; he died on that day. During this period, many
were exposed to the virus and all contacts were traced, placed under surveillance, and monitored for clinical features of EVD. The chain of EVD transmission from this single individual resulted in 19 laboratory-confirmed cases, 8 of whom succumbed to infection. Nigeria was declared EBOV free by the World Health Organization on 20 October 2014.

Between August and November 2017, we recruited 3 EVD survivors with RT-PCR positive results for EBOV, 10 individuals with documented close contact with symptomatic EVD patients, who remained healthy during the outbreak, and 6 healthcare workers (HCWs) from a different hospital in Lagos with a low likelihood of previous EBOV exposure based on proximity to the outbreak epicenter and subsequent questionnaires to eliminate potential recall bias. All methods described subsequently were performed on the Lagos samples from the EVD survivors, documented EVD contacts, and controls.

Additionally, an epidemic of EVD erupted in Yambuku, a small village near Yandongi, Democratic Republic of Congo (formerly Zaire) in 1976 [4]. In the course of epidemiological investigations of this outbreak, hundreds of serum samples were collected from residents of the surrounding areas. In 1985, these serum samples were screened for antibodies to human immunodeficiency virus (HIV) [22], and in 1988 additional screening was conducted at Harvard Chan, with excess samples stored. The availability of 71 archived samples from the first known EBOV outbreak offered an opportunity to assess EBOV-specific antibodies in serum collected from potentially EBOV exposed but presumed uninfected individuals. Only Western blot testing to EBOV fusion antigens was performed on the DRC samples for EBOV serostatus.

PBMC and plasma isolation performed at LUTH

PBMCs were separated from plasma and whole blood in EDTA tubes by Ficoll-Paque gradient density (GE Healthcare Life Sciences, Pittsburgh, PA, USA) and cryopreserved in freezing media (10% dimethyl sulfoxide [DMSO, Sigma-Aldrich, St. Louis, MO, USA], 90% fetal bovine serum [FBS, ThermoFisher Scientific, Rockford, IL, USA] at -80˚C prior to transfer to liquid nitrogen. Plasma was separately aliquoted and immediately transferred to -80˚C.

Nucleic acid testing

RNA was extracted from all plasma samples using the QIAamp RNA Viral Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions and was quantified using quantitative RT-PCR (qRT-PCR) for both EBOV and human ribosomal RNA (18S), as previously described [23]. Briefly, the assay mix included 3ul of RNA, 0.03umol/L sense and anti-sense primers, 5ul of X2 Power ZYBR Green RT-PCR Mix and 0.08ul of RT Enzyme Mix (ThermoFisher Scientific, Rockford, IL, USA). The cycling conditions were 48˚C for 30 min, 95˚C for 10 min, followed by 45 cycles of 95˚C for 15 sec, 60˚C for 30 sec with a melt curve of 95˚C for 15 sec, 55˚C for 15 sec, 95˚C for 15 sec. qRT-PCR was performed on the LightCycler 96 (Roche, Indianapolis, IN, USA). The amplicons were cleaned using AMPure XP beads (Beckman Coulter, Brea, CA, USA) according to the manufacturer’s instructions and amplicon concentrations were converted to EBOV copies per microliter for quantification.

Antigen and antibody ELISAs

All plasma samples collected from the Lagos study participants were screened by the ReEBOV IgG ELISA kit (Zalgen Lab, Germantown, MD, USA) and the EV-IgG ELISA kit (MyBioSource, San Diego, CA, USA) according to the manufacturers’ instructions. All Lagos study participants’ plasma were also screened by the ReEBOV Antigen ELISA kit (Zalgen Lab, Germantown, MD, USA) according to the manufacturer’s instructions. Measurement of OD was
performed within 5 min of stopping the reaction at 450nm (antibody) and 620nm (antigen) with the MiltiskanTM GO Plate Reader (ThermoFisher Scientific, Rockford, IL, USA).

**Construction and expression of LFn fusion proteins**

Commercially synthesized amino acid fragments corresponding to the EBOV (Makona variant) NP, VP40, GP1, and sGP were cloned into the LFn expression plasmid (pET15bLFn), which contains a T7 promoter, histidine tag, and the terminal domain of the anthrax lethal factor. The EBOV NP, VP40, GP1, and sGP sequences were derived consensus sequences generated from the initial 99 genomes initially published during the 2013–2016 outbreak [24]. The pET15bLFn containing the coding sequences of EBOV NP, VP40, and GP1 were transformed into E. coli BLR (DE3) (Millipore, Medford, MA, USA) for expression. Clones containing the correct reading frame as verified by sequencing were used for protein expression, as previously described [25]. The pET15bLFn was expressed and purified as described above for use as a negative control.

**Western blot**

All plasma samples collected from both the Lagos and DRC study participants were screened for the presence of IgG antibodies to bind to recombinant LFn-EBOV-GP1 and -sGP. Briefly, 50μg LFn-EBOV-GP1 and -sGP were added to reducing buffer (2% SDS, 0.5 M Tris [pH 6.8], 20% glycerol, 0.001% bromophenol blue, and 5% 2-Mercaptoethanol) and subjected to 12% polyacrylamide gel electrophoresis (PAGE). Western Blot analysis was conducted using plasma samples (1:100) as primary antibody and anti-human IgG HRP (ThermoFisher Scientific, Rockford, IL, USA) as secondary antibody. Visualization was performed using SuperSignal Femto Chemiluminescent Substrate (ThermoFisher Scientific, Rockford, IL, USA) and with the Chemi Doc XRS+ Imaging System (Bio Rad Technologies, Hercules, CA, USA).

**Ex vivo ELISPOT assay**

ELISPOT assays were performed as previously described [26]. Briefly, a total of 2x10⁵ PBMCs were incubated with 0.1ml complete RPMI 1640 medium (ThermoFisher Scientific, Rockford, IL, USA) in the presence of 2.5μg/ml final concentration LFn fusion proteins in antibody coated 96-well polyvinylidene difluoride (PVDF)-backed MultiScreen-HTS (MSIP) microtiter plates (Millipore, Medford, MA, USA). After 24 hr of incubation at 37˚C, the plates were washed and incubated with secondary antibodies, followed by an overnight incubation at 4˚C. Plates were washed, then incubated for 2 hr at room temperature with the enzymatic conjugate. Spots were developed using Vector Blue substrate solution (Vector Laboratories, Burlingame, CA, USA) and counted manually using a stereozoom microscope (20X magnification). In CD8 and CD4 experiments, CD8+ and CD4+ T cells were isolated from PBMCs using the CD8+ and CD4+ T cell Isolation kits (Miltenyi Biotec, Auburn, CA, USA). EBOV-specific spots were calculated by subtracting the mean of the negative control values of the replicates from the mean values of the specific stimulation. Positive responses were greater than four times the mean background, three standard deviations above the background, and ≥55 spot-forming cells per (SFC)/10⁶ PBMCs.

**Statistical analysis**

Statistical analyses, including comparison between groups of individuals and between antigens, were performed using Prism 7 (GraphPad, San Diego, CA, USA). Data are expressed as
geometric positive means ± standard deviation. Non-parametric Mann-Whitney test was used to compare data and determine statistical significance. \( p < 0.05 \) was considered significant.

Results

Antigen capture, qRT-PCR, and serology data

At the time of sample collection, all Lagos study participants recruited were healthy. The median age was 34 years (range, 24–65 years), and 37% were female. Study participant characteristics are summarized in S1 Table.

We assessed Lagos plasma samples for the presence of EBOV nucleic acid, EBOV antigen, and EBOV-specific antibodies (Table 1). All study participants tested negative for EBOV by qRT-PCR and antigen capture ELISA. Using the Zalgen ReEBOV IgG ELISA, which assesses antibodies specific to EBOV VP40, 3 of 3 EVD survivors and 2 of 10 documented EVD contacts tested positive, and all 6 control HCWs were negative. Using the MyBioSource EV-IgG ELISA, which uses inactivated and homogenized EBOV, 2 of 3 EVD survivors and the same 2 out of 10 EVD contacts tested positive while the control HCWs remained negative. Consistent with the Zalgen ReEBOV IgG ELISA, Western blot analysis using the LFn-EBOV-GP1 and -sGP fusion proteins revealed GP1- and sGP-specific IgG antibodies in the 3 EVD survivors and the same 2 out of 10 documented EVD contacts, with no detectable antibodies in the control HCWs (Fig 1).

Of the serum samples collected during the 1976 EVD epidemic in the DRC, 9 of 71 (12.7%) contained IgG antibodies that were reactive to LFn-EBOV-GP1 and/or -sGP as demonstrated by Western blot (Table 2, Fig 2). Antibodies specific to LFn-EBOV-GP1 were found in 1.4% (1/71), 9.6% (7/71) to LFn-EBOV-sGP and 1.4% (1/71) to both LFn-EBOV-GP1 and -sGP.

Ex vivo ELISPOT data

We then assessed the post-infection cellular responses in all Lagos study participants by LFn fusion protein stimulation of PBMCs in IFN-\( \gamma \) and TNF-\( \alpha \) ELISPOTs. All 3 EVD survivors and the 2 seropositive EVD contacts mounted detectable IFN-\( \gamma \) and TNF-\( \alpha \) cellular responses to LFn-EBOV-NP, -VP40, and/or -GP1 (Table 3, Fig 3). The remaining 8 documented EVD contacts and all 6 control HCWs mounted cellular responses below the positive threshold (Table 3).

In most cases, the EVD survivors and the seropositive contacts mounted the strongest IFN-\( \gamma \) and TNF-\( \alpha \) cellular against LFn-EBOV-NP, \( p < 0.05 \). (Fig 4). IFN-\( \gamma \) and TNF-\( \alpha \) cellular responses against LFn-EBOV-GP1 were stronger compared to responses against LFn-EBOV-VP40, \( p < 0.05 \). Additionally, the seropositive EVD contacts mounted IFN-\( \gamma \) and TNF-\( \alpha \) cellular responses against LFn-EBOV-NP, -VP40, and -GP1 that were stronger in magnitude compared to survivors; similarly, IFN-\( \gamma \) responses against LFn-EBOV-NP and -GP1 and for

---

**Table 1. qRT-PCR, antigen ELISA, and serology results, Lagos, Nigeria.**

| Study participants          | qRT-PCR | ReEBOV Antigen ELISA | ReEBOV IgG ELISA | EV-IgG ELISA | LFn-EBOV-GP1 Western blot | LFn-EBOV-sGP Western blot |
|----------------------------|---------|----------------------|------------------|--------------|---------------------------|---------------------------|
| EVD survivors              | 0/3     | 0/3                  | 3/3              | 2/3          | 3/3                       | 3/3                       |
| Documented EVD contacts    | 0/10    | 0/10                 | 2/10             | 2/10         | 2/10                      | 2/10                      |
| Control healthcare workers | 0/6     | 0/6                  | 0/6              | 0/6          | 0/6                       | 0/6                       |

https://doi.org/10.1371/journal.pntd.0006530.t001
TNF-α responses against LFn-EBOV-NP and -VP40 were stronger in contacts compared to survivors, p<0.05.

We further evaluated the post-infection CD8+ and CD4+ T cell responses in the EVD survivors and the seropositive EVD contacts. Due to sample availability, we assessed IFN-γ and TNF-α responses against LFn-EBOV-NP and -GP1. In nearly all cases, mean IFN-γ and TNF-α CD8+ and CD4+ responses were stronger among the seropositive EVD contacts compared to the survivors, though not statistically significant (Fig 5). As the only exception, mean IFN-γ CD4+ response against LFn-EBOV-NP was stronger in the EVD survivors compared to the seropositive contacts, though not statistically significant (Fig 5C).

**Discussion**

The characterization of the immune response in mild and asymptomatic EBOV infection may explain how certain individuals infected with this otherwise highly lethal virus avoid severe disease. This could contribute to efforts in the development of more effective vaccines and immunotherapeutics against EBOV and related filoviruses. Therefore, we adapted the modified anthrax toxin delivery system to design LFn-EBOV fusion proteins for antibody and/or T cell analyses in EVD survivors, documented close EVD contacts, and in presumed healthy individuals living in nearby areas of the 1976 EVD outbreak in the DRC.

**Table 2. Serology results, 1976 Democratic Republic of Congo.**

| 1976 DRC sera (N = 71) | LFn-EBOV-GP1 Western blot | LFn-EBOV-sGP Western blot | LFn-EBOV-GP1 + sGP Western blot |
|-------------------------|---------------------------|---------------------------|-------------------------------|
| No. positive/Total number tested (%) | 1/71 (1.4) | 1/71 (1.4) | 9/71 (12.7) |

https://doi.org/10.1371/journal.pntd.0006530.t002
T cell responses in survivors of EVD epidemics has been relatively well studied. Four patients with acute EVD demonstrated CD8+ and CD4+ T cell activation against several viral proteins, and this activation persisted for up to one month after infection [17]. Consistent with this study, prolonged T cell activation was observed in a single patient who cleared EBOV infection without the use of experimental drugs [27]. Another study evaluating patients during the acute phase of infection, demonstrated that survivors have T cells that express lower levels of the inhibitory molecules CTLA-4 and PD-1, compared to fatal EVD cases with high viral load [20]. Additionally, a study of SUDV survivors, 12 years post infection, demonstrated strong memory CD4+, but not CD8+, T cell activation and neutralizing humoral immunity [28]. Whole irradiated SUDV was used to stimulate PBMC samples in these long-recovered survivors, likely contributing to the limited CD8+ activation.

Moreover, minimally symptomatic and asymptomatic EBOV infections are not new phenomena. Using an immunofluorescence assay, World Health Organization researchers identified EBOV-infected individuals who had symptoms that ranged in severity, from mild to rapidly fatal, during the first outbreaks of EBOV in Zaire and Sudan in 1976 and 1979, respectively [4, 5, 29]. Since then, a number of additional studies utilizing diverse methods have identified EBOV-infected individuals who nonetheless remained asymptomatic [30–34]. However, studies examining the cellular immune responses during mild or asymptomatic infection are scarce. In one study of Gabonese individuals with asymptomatic EVD infection, high

Fig 2. Detection of EBOV antibodies, 1976 Democratic Republic of Congo. (A) Representative image of reactive LFn-EBOV-GP and LFn-EBOV-sGP Western blot analysis in 9 sera collected in surrounding areas of the 1976 Ebola virus outbreak in the Democratic Republic of Congo. +, positive control. Molecular size marker units are kDa. EVD, Ebola virus disease.

https://doi.org/10.1371/journal.pntd.0006530.g002
Table 3. Ex vivo ELISPOT results using the LFn-EBOV fusion proteins, Lagos, Nigeria.

| Study participants | EBOV seropositive | IFN-γ+ SFC / 10^6 PBMC | TNF-α+ SFC / 10^6 PBMC |
|--------------------|-------------------|-------------------------|-------------------------|
|                    |                   | LFn EBOV NP | LFn EBOV VP40 | LFn EBOV GP1 | LFn EBOV NP | LFn EBOV VP40 | LFn EBOV GP1 |
| **EVD survivors**  |                   |             |               |               |             |               |               |
| EV01               | Y                 | 572         | 187           | 400           | 522         | 84           | 440           |
| EV02               | Y                 | 418         | 30            | 366           | 455         | 29           | 120           |
| EV03               | Y                 | 508         | 75            | 313           | 337         | 120          | 383           |
| **Documented EVD contacts** | |             |               |               |             |               |               |
| EV04               | Y                 | 705         | 135           | 552           | 605         | 165          | 498           |
| EV05               | Y                 | 770         | 250           | 590           | 670         | 214          | 562           |
| EV06               | N                 | 12          | 9             | 14            | 5           | 12           | 13            |
| EV07               | N                 | 23          | 17            | 18            | 10          | 15           | 16            |
| EV08               | N                 | 7           | 9             | 13            | 7           | 9            | 8             |
| EV09               | N                 | 33          | 20            | 18            | 8           | 4            | 7             |
| EV10               | N                 | 6           | 10            | 8             | 8           | 9            | 11            |
| EV11               | N                 | 2           | 12            | 7             | 15          | 14           | 18            |
| EV12               | N                 | 14          | 9             | 13            | 4           | 6            | 12            |
| EV13               | N                 | 10          | 12            | 6             | 8           | 12           | 11            |
| **Controls healthcare workers** | |             |               |               |             |               |               |
| EV14               | N                 | 8           | 3             | 12            | 5           | 11           | 7             |
| EV15               | N                 | 16          | 13            | 23            | 9           | 10           | 6             |
| EV16               | N                 | 27          | 14            | 19            | 12          | 6            | 17            |
| EV17               | N                 | 16          | 7             | 9             | 5           | 10           | 11            |
| EV18               | N                 | 3           | 8             | 13            | 4           | 7            | 12            |
| EV19               | N                 | 12          | 21            | 16            | 14          | 9            | 8             |

https://doi.org/10.1371/journal.pntd.0006530.t003

Fig 3. Cellular immune responses, Lagos, Nigeria. PBMC samples from the EVD survivors, documented EVD contacts, and control HCWs were treated with the LFn-EBOV fusion proteins and the IFN-γ+ and TNF-α+ cellular responses were detected by LFn ELISPOT ex vivo experiments. Representative images of IFN-γ (A) and TNF-α (B) cellular responses when stimulated with the LFn-Ebola virus fusion proteins. NP, LFn-EBOV-NP. VP40, LFn-EBOV-VP40. GP1, LFn-EBOV-GP1. LFn, negative control. PHA, phytohemagglutinin, positive control.

https://doi.org/10.1371/journal.pntd.0006530.g003
concentrations of pro-inflammatory cytokines were detected in plasma samples; yet, no T cell-derived cytokines were observed [33]. A follow-up study in the same individuals demonstrated mRNA expression of T cell cytokines and cytotoxic activation markers, suggesting cytotoxic T cell activation; however, EBOV-specific activation was not studied [35].

Fig 4. Ex vivo cellular reactivity to EBOV LFn fusion proteins, Lagos, Nigeria. PBMC samples from the EVD survivors and documented EVD contacts were treated with the LFn-EBOV fusion proteins and the IFN-γ+ and TNF-α+ cellular responses were detected by LFn ELISPOT ex vivo experiments. Average magnitude of convalescent IFN-γ (A) and TNF-α (B) responses are shown. Dotted lines represent the cut-off value. Control HCWs, control healthcare workers. *, p < 0.05.

https://doi.org/10.1371/journal.pntd.0006530.g004

Fig 5. Ex vivo CD8+ and CD4+ cellular reactivity to EBOV LFn fusion proteins, Lagos, Nigeria. CD8+ and CD4+ cells from the EVD survivors and documented EVD contacts were treated with the LFn-EBOV fusion proteins and the IFN-γ+ and TNF-α+ responses were detected by LFn ELISPOT ex vivo experiments. Individual and mean CD8+ IFN-γ+ (A) and TNF-α+ (B) and CD4+ IFN-γ+ (C) and TNF-α+ (D) responses are shown. Dotted lines represent the cut-off value. Control HCWs, control healthcare workers. *, p < 0.05.

https://doi.org/10.1371/journal.pntd.0006530.g005
In this study, we demonstrated for the first time, to our knowledge, EBOV-specific cellular responses in seropositive asymptomatic individuals as well as EVD survivors. The seropositive asymptomatic individuals mounted stronger IFN-γ and TNF-α responses to all three LFn-EBOV fusion proteins (LFn-EBOV-NP, -VP40, and -GP1) compared to the EVD survivors. Cellular responses were significantly stronger for IFN-γ responses to LFn-EBOV-NP and LFn-EBOV-GP1 and for TNF-α responses LFn-EBOV-NP and LFn-EBOV-VP40. Consistent with previous studies, cellular responses directed to the EBOV NP were strongest compared to other EBOV antigens, in both the EVD survivors and the seropositive asymptomatic individuals. We also showed that seropositive asymptomatic individuals have IFN-γ and TNF-α cellular responses that were stronger when compared to the survivors. These results suggest that T cell immunity may play a protective role against severe EVD. Additionally, we detected EBOV-specific antibodies in serum collected from individuals living in surrounding areas of the 1976 EVD epidemic in the DRC. These results further support undiagnosed EBOV infection in individuals living in EBOV endemic regions.

While the study of long recovered SUDV survivors was unable to elicit CD8+ T cells, our study demonstrates robust CD8+ T cells against the LFn-EBOV fusion proteins in 3-year post-infection EVD survivors and 2 contacts not known to have ever been infected by EBOV. The LFn-EBOV fusion proteins elicit specific and sensitive T cell responses with low background signals in ELISPOP. Thus, LFn-EBOV priming systems may offer utility as an alternative and inexpensive technology for ex vivo screening of EBOV-specific T cell responses in future vaccine clinical trials. Additionally, our detection of both EBOV-specific CD8+ and CD4+ T cell responses suggests that the LFn delivery system is capable of efficiently presenting exogenous EBOV proteins to the MHC class I and II pathways; therefore, the use of LFn-EBOV fusion constructs presents an attractive technology for EBOV antigen delivery in vaccine design.

Our study has several limitations. Our study population is small and we recruited only a limited number of individuals with documented close EVD contact. It is likely that there are more individuals who were infected with EBOV and remained healthy during the outbreak in Nigeria. While we used different tests to identify individuals with markers of EBOV infection, we did not perform microneutralization assays to confirm infection specificity or define antiviral function of the antibodies detected in either the EVD survivors or the seropositive asymptomatic individuals. Future studies are expected to examine the functional characteristics of antibodies in minimally symptomatic and asymptomatic EBOV infections. We also demonstrated that the seropositive asymptomatic individuals have stronger T cell responses compared to the EVD survivors; however, additional studies with more study participants are needed to validate these results. We cannot rule out the possibility that the asymptomatic individuals were exposed to a low inoculum or dead antigen, precluding the development of EVD, and generated EBOV-specific T cell responses. Whether these CD8+ and CD4+ cells remain functional during secondary exposure to EBOV remains to be elucidated. Future studies investigating T cell functional markers such as PD-1 and CTLA-4 among the seropositive asymptomatic individuals are expected.

In conclusion, our findings raise new questions and highlight the need for further investigation to better understand the immune responses associated with minimally symptomatic and asymptomatic EBOV infections. By development of the LFn-EBOV ELISPOP assay, we detected cellular immune responses in EVD survivors and individuals with documented close contact with EVD patients, approximately three years after the outbreak in Lagos, Nigeria. These results suggest the importance of T cell responses in disease progression and have important implications for vaccine development, as well as for potential EBOV diagnostics based on T cell responses.
Supporting information

S1 Checklist. STROBE checklist. (DOC)

S1 Table. List and characteristics of participants used in this study. (XLSX)

Acknowledgments

We wish to acknowledge the courage, dedication, and sacrifice of the leadership and staff at First Consultant’s Hospital in Lagos, Nigeria. We thank them and our study participants for their commitment to research on this deadly pathogen. We thank Nicholas Kushner and Neal Touzjian for technical advice with the modified anthrax delivery system.

Author Contributions

Conceptualization: Bobby Brooke Herrera, Alani S. Akanmu, Folasade Ogunsola, Phyllis J. Kanki.

Data curation: Bobby Brooke Herrera, Philip Oshun, Charlotte A. Chang.

Formal analysis: Bobby Brooke Herrera, Charlotte A. Chang.

Funding acquisition: Folasade Ogunsola, Phyllis J. Kanki.

Investigation: Bobby Brooke Herrera, Donald J. Hamel, Philip Oshun, Rolake Akinsola, Alani S. Akanmu, Philomena Eromon, Onikepe Folarin, Kayode T. Adeyemi, Christian T. Happi.

Methodology: Bobby Brooke Herrera, Donald J. Hamel, Alani S. Akanmu, Christian T. Happi, Yichen Lu.

Project administration: Charlotte A. Chang, Phyllis J. Kanki.

Resources: Yichen Lu.

Supervision: Alani S. Akanmu, Phyllis J. Kanki.

Validation: Donald J. Hamel, Christian T. Happi.

Writing – original draft: Bobby Brooke Herrera.

Writing – review & editing: Donald J. Hamel, Philip Oshun, Rolake Akinsola, Alani S. Akanmu, Charlotte A. Chang, Philomena Eromon, Onikepe Folarin, Kayode T. Adeyemi, Christian T. Happi, Yichen Lu, Folasade Ogunsola, Phyllis J. Kanki.

References

1. Feldmann H, Sanchez A, Geisbert TW. Fields Virology. 6th ed: Wolters Kluwer Health Aids (ESP); 2013.

2. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol. 2010; 155(12):2083–103. https://doi.org/10.1007/s00705-010-0814-x PMID: 21046175; PubMed Central PMCID: PMCPMC3074192.

3. Macneil A, Reed Z, Rollin PE. Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis. 2011; 5(6):e1175. https://doi.org/10.1371/journal.pntd.0001175 PMID: 21666792; PubMed Central PMCID: PMCPMC3110169.

4. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978; 56(2):271–93. PMID: 307456; PubMed Central PMCID: PMCPMC2395567.
5. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ. 1978; 56(2):247–70. PMID: 307455; PubMed Central PMCID: PMCPMC2395561.

6. Feldmann H. Ebola—a growing threat? N Engl J Med. 2014; 371(15):1375–8. https://doi.org/10.1056/NEJMep1405314 PMID: 24805988.

7. Kucharski AJ, Edmunds WJ. Case fatality rate for Ebola virus disease in west Africa. Lancet. 2014; 384(9950):1260. https://doi.org/10.1016/S0140-6736(14)61706-2 PMID: 25260235.

8. WHO. Ebola Situation Report—30 March 2016. 2016. Available from: http://apps.who.int/ebola/ebola-situation-reports.

9. Richardson ET, Kelly JD, Barrie MB, Mesman AW, Karku S, Quiwa K, et al. Minimally Symptomatic Infection in an Ebola ‘Hotspot’: A Cross-Sectional Serosurvey. PLoS Negl Trop Dis. 2016; 10(11):e0005087. https://doi.org/10.1371/journal.pntd.0005087 PMID: 27846221; PubMed Central PMCID: PMCPMC5112953.

10. Bower H, Glynn JR. A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection. Sci Data. 2017; 4:160133. https://doi.org/10.1038/sdata.2016.133 PMID: 28140390; PubMed Central PMCID: PMCPMC5283061 of interest. Both authors have had had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

11. Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One. 2012; 7(4):e36192. https://doi.org/10.1371/journal.pone.0036192 PMID: 22558378; PubMed Central PMCID: PMCPMC3338609.

12. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012; 4(138):138ra81. https://doi.org/10.1126/scitranslmed.3003876 PMID: 22700957.

13. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520):47–53. https://doi.org/10.1038/nature13777 PMID: 25171469; PubMed Central PMCID: PMCPMC4214273.

14. Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, et al. Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis. 2016; 214(suppl 3):S367–S74. https://doi.org/10.1093/infdis/jiw333 PMID: 27571900; PubMed Central PMCID: PMCPMC5050484.

15. Jahrling PB, Geisbert JT, Swarengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis. 2007; 196 Suppl 2:S400–3. https://doi.org/10.1086/520587 PMID: 17940976.

16. Group PIW, Multi-National PIIST, Davey RT Jr., Dodd L, Proshchan MA, Neaton J, et al. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016; 375(15):1448–56. https://doi.org/10.1056/NEJMoa1604330 PMID: 27732819; PubMed Central PMCID: PMCPMC5086427.

17. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A. 2015; 112(15):4719–24. https://doi.org/10.1073/pnas.1502619112 PMID: 25775992; PubMed Central PMCID: PMCPMC4403189.

18. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011; 17(9):1128–31. https://doi.org/10.1038/nm.2447 PMID: 21857654.

19. Stanley DA, Honko AN, Asiedu C, Trefy JC, Lau-Kiby AW, Johnson JC, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014; 20(10):1126–9. https://doi.org/10.1038/nm.3702 PMID: 25194571.

20. Ruibal P, Oestreicher L, Ludtke A, Becker-Ziaja B, Wozniak DM, Kerber R, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016; 533(7601):100–4. https://doi.org/10.1038/nature17949 PMID: 27147028; PubMed Central PMCID: PMCPMC4679690.

21. Shuaib F, Gunnala R, Musa EO, Mahoney FJ, Oguntimehin O, Nguku PM, et al. Ebola virus disease outbreak—Nigeria, July-September 2014. MMWR Morb Mortal Wkly Rep. 2014; 63(39):867–72. PMID: 25275332.

22. Nzilambi N, De Cock KM, Forthal DN, Francis H, Ryder RW, Malebe I, et al. The prevalence of infection with human immunodeficiency virus over a 10-year period in rural Zaire. N Engl J Med. 1988; 318(5):276–8. https://doi.org/10.1056/NEJM198802043180503 PMID: 3336420.

23. Folarin OA, Ehiuchiya D, Schaffner SF, Winnicki SM, Wohl S, Eromon P, et al. Ebola Virus Epidemiology and Evolution in Nigeria. J Infect Dis. 2016; 214(suppl 3):S102–S9. https://doi.org/10.1093/infdis/jiw190 PMID: 27377746; PubMed Central PMCID: PMCPMC5050462.

24. Gire SK, Goba A, Andersen KG, Seafon RS, Park DJ, Kanneh L, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014; 345(6202):1369–72.
25. Kushner N, Zhang D, Touzjian N, Essex M, Lieberman J, Lu Y. A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen. Proc Natl Acad Sci U S A. 2003; 100 (11):6652–7. https://doi.org/10.1073/pnas.1131930100 PMID: 12740437; PubMed Central PMCID: PMCPMC164502.

26. Sarr AD, Lu Y, Sankale JL, Eisen G, Popper S, Mboup S, et al. Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunosspot assay. AIDS Res Hum Retroviruses. 2001; 17(13):1257–64. https://doi.org/10.1089/088922201750461311 PMID: 11559425.

27. Dahlke C, Lunemann S, Kasonta R, Kreuels B, Schmiedel S, Ly ML, et al. Comprehensive Characterization of Cellular Immune Responses Following Ebola Virus Infection. J Infect Dis. 2017; 215(2):287–92. https://doi.org/10.1093/infdis/jiw508 PMID: 27799354.

28. Sobanator A, Stonier SW, Herbert AS, Ochayon DE, Kuehne AI, Eskira Y, et al. Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors. Viruses. 2016; 8(5). https://doi.org/10.3390/v8050133 PMID: 27187443; PubMed Central PMCID: PMCPMC4885088.

29. Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ. 1983; 61(6):997–1003. PMID: 6370486; PubMed Central PMCID: PMCPMC2536233.

30. Busico KM, Marshall KL, Ksiazek TG, Roels TH, Fleerackers Y, Feldmann H, et al. Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. J Infect Dis. 1999; 179 Suppl 1:S102–7. https://doi.org/10.1086/514309 PMID: 9988172.

31. Georges AJ, Leroy EM, Renaut AA, Benissan CT, Nabias RJ, Ngoc MT, et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994–1997: epidemiologic and health control issues. J Infect Dis. 1999; 179 Suppl 1:S65–75. https://doi.org/10.1086/514290 PMID: 9988167.

32. Gonzalez JP, Nakoune E, Slenczka W, Vidal P, Morvan JM. Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic. Microbes Infect. 2000; 2(1):39–44. PMID: 10717539.

33. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000; 355 (9222):2210–5. PMID: 10881895.

34. Mulangu S, Borchert M, Pawska J, Tshomba A, Afounde A, Kulidri A, et al. High prevalence of IgG antibodies to Ebola virus in the Efe pygmy population in the Watsa region, Democratic Republic of the Congo. BMC Infect Dis. 2016; 16:263. https://doi.org/10.1186/s12879-016-1607-y PMID: 27286990; PubMed Central PMCID: PMCPMC4901429.

35. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol. 2001; 124(3):453–60. https://doi.org/10.1046/j.1365-2249.2001.01317.x PMID: 11472407; PubMed Central PMCID: PMCPMC1906073.